Live Breaking News & Updates on Engineered Exosomes

Stay updated with breaking news from Engineered exosomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Global Exosome Market Research Report 2023: To Date, 3 Pharma Companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have Signed Partnership Deals with Exosome Companies

/PRNewswire/ The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com s offering.. ....

Giovanni Camussi , Susanne Gabrielsson , Laura Wood , Karolinska Institutet , Exosome Research , E St Office Hours Call , Office Hours Call , Vaccine Development , Companies Developing Engineered Exosome , Funding For Exosome Research , Market For Exosome Research Products , Categories Of Exosome Companies , Jazz Pharmaceuticals , Companies Offering Exosome , Exosome Research Publications , Fresenius Medical Care , Fund Raising In Exosome Space , Roche Pharmaceutical Company , Exosome Administration , Research To Inhibit Disease , Common Isolation Methods In Exosome Research , Global Exosome Market , Exodx Prostate Intelliscore Test , Professor Giovanni , Topics Covered , Engineered Exosomes ,

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio

-Portfolio Will Now Include Exclusive Rights to Engineered Exosomes for Vaccines and Therapeutics-
/EIN News/ LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
This exclusive license agreement with JHU allows Capricor to continue the expansion of our engineered exosome platform technology. We are focused on developing this platform to deliver nucleic acids or proteins effectively into cells and drive the expression of functional proteins,” said Linda Marbán, Ph.D., CEO, Capricor Therapeutics. “This agreement marks a significant mil ....

Caitlin Kasunich Raquel Cona , Linda Marb , Stephen Gould , Joyce Allaire , Johns Hopkins University , Lifesci Advisors , Exchange Commission On , Company Contact , Strategic Communications , Capricor Therapeutics Inc , Portfolio Will Now Include Exclusive Rights , Engineered Exosomes , Biological Chemistry , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Investigational New Drug , Sci Advisors , Chief Financial , ஸ்டீபன் கூல்ட் , மகிழ்ச்சி அல்லேர் , ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம் , பரிமாற்றம் தரகு ஆன் , நிறுவனம் தொடர்பு , மூலோபாய தகவல்தொடர்புகள் , உயிரியல் வேதியியல் ,